Caribou's Blood Cancer Candidate Shows Response Rates Better Than Novartis,' This Analyst Writes
Last week, Caribou Biosciences Inc (NASDAQ: CRBU) announced Q2 earnings and provided updated results from the Phase 1 ANTLER trial of the company's lead asset—CB-010 for relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).
HC Wainright reiterated the Buy rating while lowering the price target from $28 to $27.
In six efficacy evaluable r/r NHL patients, CB-010 achieved a 100% objective response rate (ORR) and 100% complete response (CR) rate, with three of six patients (50%) maintaining the CR at the six months after one dose at the initial dose level.
Three of six patients remain in therapy.
CB-010's response rates as more competitive than seen with the FDA-approved autologous CAR-T agents, says, HC Wainwright.
The analyst notes that Gilead Sciences Inc's (NASDAQ: GILD) Yescarta demonstrated a 72% ORR (51% CR) and 91% ORR (60% CR) in DLBCL and FL, respectively.
Novartis AG's (NYSE: NVS) Kymriah demonstrated a 50% ORR (32% CR) and 86% ORR (68% CR) in DLBCL and FL, respectively.
HC Wainwright acknowledges the small sample size and the concern around the durability of response for allogeneic therapies while noting that in preclinical studies, CB-010 maintains persistent tumor eradiation longer than conventional.
Price Action: CRBU shares are down 4.61% at $9.93 on the last check Thursday.
Latest Ratings for CRBU
Date | Firm | Action | From | To |
|---|---|---|---|---|
Feb 2022 | RBC Capital | Initiates Coverage On | Outperform | |
Feb 2022 | Brookline Capital | Initiates Coverage On | Buy | |
Dec 2021 | Oppenheimer | Initiates Coverage On | Outperform |
View More Analyst Ratings for CRBU
View the Latest Analyst Ratings
See more from Benzinga
Blueprint Medicines' Ayvakit 'Will Garner Approval' Despite Questions, This Analyst Says
Analysts Are Bullish On 89bio's NASH Data Slated For Early Next Year
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
